Sperm Selection by Either PICSI or MACS in Cases With Abnormal Sperm DNA Fragmentation Index for ICSI

Sponsor
Ganin Fertility Center (Other)
Overall Status
Completed
CT.gov ID
NCT03398317
Collaborator
The Cleveland Clinic (Other), University of the Western Cape (Other)
396
1
2
26.9
14.7

Study Details

Study Description

Brief Summary

On the day of ICSI, choosing the best sperm by either PICSI or magnetic activated cell sorting (MACS) in cases with abnormal DNA is not fully investigated. This study helps in solving this problem by using two known techniques to achieve that purpose.

Condition or Disease Intervention/Treatment Phase
  • Other: PICSI
  • Other: MACS
N/A

Detailed Description

Sperm DNA fragmentation has shown a negative correlation with fertilization rate, embryo quality, and implantation rate. And a positive correlation with miscarriage rate in the 1st trimester.

Sperm selection methods like PICSI and MACS have been developed for selecting a healthy mature non apoptotic sperm with healthy membrane for Oocyte injection so as to obtain best embryo quality and achieve higher ongoing pregnancy rates.

A sperm selection technique based on sperm membrane binding to hyaluronic acid (PICSI Dish), the main substrate of the oocyte zonapellucida, could improve the likelihood of obtaining better sperm for ICSI with non fragmented DNA. Another sperm selection technique based on Magnetic activated cell sorting (MACS) that depends on the binding of protein Annexin V to phosphatidylserine which is a marker for apoptosis, giving a resulting (eluted) spermatozoa without DNA fragmentation.

In order to determine which sperm selection technique is better for dealing with DNA fragmentation patients we need to study both techniques on two different groups of patients

Study Design

Study Type:
Interventional
Actual Enrollment :
396 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
PICSI vs. MACS for Abnormal Sperm DNA Fragmentation ICSI Cases: a Prospective Randomized Trial
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Mar 30, 2019
Actual Study Completion Date :
Mar 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: PICSI

Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection

Other: PICSI
sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index

Active Comparator: MACS

Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.

Other: MACS
sperm selection using MACS for selecting sperm with lower DNA fragmentation index

Outcome Measures

Primary Outcome Measures

  1. Ongoing pregnancy rate [20 weeks of gestation]

    Defined as the proportion of pregnancies that completed more than 20 weeks of gestation

Secondary Outcome Measures

  1. Comparison of cleavage rate [3 days]

    Defined as the proportion of cleaved embryos on day 3 over the injected oocytes

  2. Comparison of Blastulation rate [5-6 days]

    Defined as the proportion of blastocysts formed on day 5 or 6 over the cleaved embryos on day 3

  3. Comparison of Blastocyst quality rate [5-6 days]

    Defined as the assessment of blastocyst quality according to Gardner's criteria into: good, fair or bad in terms of percentage of the total formed blastocysts

  4. Comparison of Pregnancy rate [14 days following embryo transfer]

    Defined as clinical pregnancy per transfer

  5. Comparison of implantation rate [6- 8 weeks following embryo transfer]

    Defined as number of gestational sacs with fetal heart beat, shown by ultrasound in gestational week 6 over number of embryo transferred.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males diagnosed of abnormal DNA fragmentation index ( > 19%).

  • Males with mild to moderate OTA (oligoteratoasthenozoospermia).

  • Male aged 18-60 years.

  • Female aged 18-40 years.

  • Normo responder ( > 5 mature oocytes)

  • Male will have to refrain from ejaculation no less than 1 day but no greater than 3 days prior semen specimen production on day of oocyte retrieval

Exclusion Criteria:

Males with normalDNA fragmentation index (<19%)at the initial assessment.

  • Leukocytospermia

  • Presence of varicocele.

  • Known genetic abnormality

  • Use of sperm donation or cryopreserved sperm

  • Use of Oocyte donation

  • Use of gestational carrier

  • Presence of any of the endometrial factors that affect embryo implantation such as hydrosalpings, adenomyosis or previous uterine infection

  • Any contradictions to undergoing in vitro fertilization or gonadotropin stimulation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ganin Fertility Center Cairo Egypt

Sponsors and Collaborators

  • Ganin Fertility Center
  • The Cleveland Clinic
  • University of the Western Cape

Investigators

  • Study Chair: Hosam Zaki, MSc, FRCOG, Ganin Fertility Center, Cairo, Egypt
  • Principal Investigator: Eman Hasanen, BSc, Ganin Fertility Center, Cairo, Egypt
  • Principal Investigator: Khaled El Qusi, BSc, Ganin Fertility Center, Cairo, Egypt
  • Principal Investigator: Abd El Ghafar Hussin, BSc, Ganin Fertility Center, Cairo, Egypt
  • Principal Investigator: Salma El Tanbouly, BSc, Ganin Fertility Center, Cairo, Egypt
  • Study Director: Ashok Agarwal, PhD, American Center of Reproductive Medicine, Cleveland Clinic
  • Principal Investigator: Ralph Henkel, PhD, University of the Western Cape
  • Principal Investigator: Hanaa Alkhader, Ganin Fertility Center, Cairo, Egypt

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Eman Hasanen, Clinical Embryologist, Ganin Fertility Center
ClinicalTrials.gov Identifier:
NCT03398317
Other Study ID Numbers:
  • GFC - 002
First Posted:
Jan 12, 2018
Last Update Posted:
Jul 21, 2020
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eman Hasanen, Clinical Embryologist, Ganin Fertility Center

Study Results

No Results Posted as of Jul 21, 2020